B. Quesnel

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
B C Quesnel, B Quesnel, B. Quesnel, Bruno Quesnel
Publication record
296 papers · 14,312 citations · H-index 61

PAPERS

Topic: AS01-Diagnosis/AS01c-Molecular aberrations (cytogenetic, genetic, gene expression): PRATICAL USE OF MONOCYTE SUBSET BY FLOW CYTOMETRY AND SEQUENCING IN DIAGNOSIS AND PROGNOSIS OF CLINICAL RELEVANT MONOCYTOSIS
20230 citationsauthor #16
Single-agent 5-azacytidine as post-transplant maintenance in high-risk myeloid malignancies undergoing allogeneic hematopoietic cell transplantation
20227 citationsauthor #7
Resurgence of myeloproliferative neoplasm in patients in remission from blast transformation after treatment with hypomethylating agents.
20220 citationsauthor #8
Pyrazolones as inhibitors of immune checkpoint blocking the PD-1/PD-L1 interaction.
202221 citationsauthor #12
Successful bridging to cell therapy for relapsed/refractory acute lymphoblastic leukaemia with a combination of venetoclax and PEG‐asparaginase
20222 citationsauthor #3
Detection of residual and chemoresistant leukemic cells in an immune-competent mouse model of acute myeloid leukemia: Potential for unravelling their interactions with immunity
20223 citationsauthor #7
Involvement of ORAI1/SOCE in Human AML Cell Lines and Primary Cells According to ABCB1 Activity, LSC Compartment and Potential Resistance to Ara-C Exposure
20227 citationsauthor #15
Put in a “Ca2+ll” to Acute Myeloid Leukemia
20228 citationsauthor #3
P851: TARGETING GENE DEPENDENCIES IN MYC OVEREXPRESSING MULTIPLE MYELOMA
20220 citationsauthor #13
A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher‐Risk MDS or low blast AML: GFM's “pick a winner” trial, with the impact of somatic mutations
202217 citationsauthor #24
221P The role of TNF-alpha in thymus dysfunction during acute myeloid leukemia
20220 citationsauthor #3
[GATA2 gene mutations: 3 cases].
20220 citationsauthor #3
Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors
202216 citationsauthor #5
Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells
202110 citationsauthor #17
Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience
2021126 citationsauthor #7
Expanded Access Program: Evaluating Safety of Erythrocytes Encapsulating L-Asparaginase in Combination with Polychemotherapy in Patients Under 55 Years Old with Acute Lymphoblastic Leukaemia (ALL) at Risk to Receive Other Formulations of Asparaginase
20212 citationsauthor #6
Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases
2021101 citationsauthor #3
Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)
2021223 citationsauthor #18
Bimodal expression of RHOH during myelomonocytic differentiation: Implications for the expansion of AML differentiation therapy
20214 citationsauthor #8
Acute Myeloid Leukemia: Is It T Time?
20218 citationsauthor #3
Modulation of the Gal-9/TIM-3 Immune Checkpoint with α-Lactose. Does Anomery of Lactose Matter?
202116 citationsauthor #3
Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML
202110 citationsauthor #16
Systemic Pulmonary Events Associated with Myelodysplastic Syndromes: A Retrospective Multicentre Study
20215 citationsauthor #8
Clinically Relevant Oxygraphic Assay to Assess Mitochondrial Energy Metabolism in Acute Myeloid Leukemia Patients
20215 citationsauthor #8
Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis
202111 citationsauthor #5
Phase 1 first-in-human study of ABBV-184 monotherapy in adult patients with previously treated acute myeloid leukemia or non-small cell lung cancer.
20210 citationsauthor #7
Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)
202130 citationsauthor #26
p65/RelA NF‐κB fragments generated by RIPK3 activity regulate tumorigenicity, cell metabolism, and stemness characteristics
20215 citationsauthor #13
Aggressiveness Potential of Spontaneous Canine Mucosal Melanoma Can Dictate Distinct Cancer Stem Cell Compartment Behaviors in Regard to Their Initial Size and Expansion Abilities
20205 citationsauthor #6
Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant IDH1 AML: Results from Matched Comparisons to Historical Controls
20203 citationsauthor #13
Disease escape with the selective loss of the Philadelphia chromosome after tyrosine kinase inhibitor exposure in Ph-positive acute lymphoblastic leukemia
20202 citationsauthor #10
Clinico-Biological Features and Clonal Hematopoiesis in Patients with Severe COVID-19
202026 citationsauthor #22
Measurement of Protein-Protein Interactions through Microscale Thermophoresis (MST).
202016 citationsauthor #4
MDS-175: Assessment of Dose-Dependent Response to Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) with Ring Sideroblasts (RS) in the Phase 3 MEDALIST Trial
20200 citationsauthor #12
Acute myeloid leukemia synchronous with multiple myeloma successfully treated by azacytidine/lenalidomide and daratumumab without a decrease in myeloid clone size
20208 citationsauthor #7
Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times
2020194 citationsauthor #3
Antimetabolic Cooperativity with l-Asparaginase and Tyrosine Kinase Inhibitor Quizartinib to Eradicate Persistant FLT3-ITD Leukemic Cells
20201 citationsauthor #5
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
2020422 citationsauthor #23
MDS-171: Effects of Luspatercept on Serum Ferritin in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) with Ring Sideroblasts (RS) in the Phase 3 MEDALIST Trial
20201 citationsauthor #7
Mitochondrial Spare Reserve Capacity : A New Predictive Metabolic Biomarker for Aggressiveness of Acute Myeloid Leukemia
20201 citationsauthor #2
Antimetabolic cooperativity with the clinically approved kidrolase and tyrosine kinase inhibitors to eradicate cml stem cells
20200 citationsauthor #15
Abstract 5340: Novel small-molecule antagonists of the PD1/PD-L1 axis
20200 citationsauthor #8
Discontinuation of antimicrobial therapy in adult neutropenic haematology patients: A prospective cohort.
201923 citationsauthor #20
MYC Overexpressing Multiple Myeloma Are Dependent on GLS1
20190 citationsauthor #8
Familial myeloid malignancies with germline TET2 mutation
201942 citationsauthor #14
PS1041 TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH IDH2-MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA – A FRENCH MEDICAL CHART REVIEW ANALYSIS
20190 citationsauthor #2
Inherited transmission of the CSF3R T618I mutational hotspot in familial chronic neutrophilic leukemia.
201918 citationsauthor #12
Deregulation and Targeting of TP53 Pathway in Multiple Myeloma
201966 citationsauthor #9
How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?
201998 citationsauthor #40
Abstract 2671: Omics unveils a specific signature of tumor dormancy in two murine models of leukemia and melanoma
20190 citationsauthor #14
APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des Myélodysplasies (GFM)
201970 citationsauthor #18
CD9 in acute myeloid leukemia: Prognostic role and usefulness to target leukemic stem cells
201929 citationsauthor #6
A Randomized Phase II Study of Azacitidine (AZA) Alone or with Lenalidomide (LEN), Valproic Acid (VPA) or Idarubicin (IDA) in Higher-Risk MDS: Gfm's 'pick a Winner' Trial
201813 citationsauthor #23
Isolation and characterization of two canine melanoma cell lines: new models for comparative oncology
201814 citationsauthor #11
Comprehensive molecular landscape in patients older than 80 years old diagnosed with acute myeloid leukemia: A study of the French Hauts‐de‐France AML observatory
20188 citationsauthor #15
CAR T-cells: A John von Neumann legacy?
201813 citationsauthor #1
The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions
201861 citationsauthor #23
PO-264 Mitochondrial metabolism: a key factor of myeloid leukemic cell response upon exposure to tyrosine kinase inhibitors
20180 citationsauthor #8
Glucose metabolism and NRF2 coordinate the antioxidant response in melanoma resistant to MAPK inhibitors
201878 citationsauthor #15
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up.
201814 citationsauthor #7
Abstract 384: Role of PD-L1 immunoregulatory protein in breast cancer cells metabolic reprogramming
20180 citationsauthor #7
Sub-clonal analysis of the murine C1498 acute myeloid leukaemia cell line reveals genomic and immunogenic diversity.
20175 citationsauthor #7
TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia
201783 citationsauthor #17
Impact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML
201731 citationsauthor #11
Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma
201760 citationsauthor #14
Metabolic rewiring in cancer cells overexpressing the glucocorticoid-induced leucine zipper protein (GILZ): Activation of mitochondrial oxidative phosphorylation and sensitization to oxidative cell death induced by mitochondrial targeted drugs.
201714 citationsauthor #7
Targeting MYC in multiple myeloma
2017115 citationsauthor #5
Copy-number analysis identified new prognostic marker in acute myeloid leukemia
201737 citationsauthor #16
in MDS patients treated with AZA. Its prognostic value may be further improved by specific scoring systems established for AZA treatment such as the one we described previously.3
20170 citationsauthor #5
PD-1/PD-L1 binding studies using microscale thermophoresis
201761 citationsauthor #5
Role of IRF4 in resistance to immunomodulatory (IMid) compounds® in Waldenström’s macroglobulinemia
20176 citationsauthor #12
Accumulation of classical monocytes defines a subgroup of MDS that frequently evolves into CMML.
201764 citationsauthor #6
Randomized Phase 2 Trial of Lirilumab (anti-KIR monoclonal antibody, mAb) As Maintenance Treatment in Elderly Patients (pts) with Acute Myeloid Leukemia (AML): Results of the Effikir Trial
201735 citationsauthor #14
Haemodynamically proven pulmonary hypertension in a patient with GATA2 deficiency-associated pulmonary alveolar proteinosis and fibrosis
201712 citationsauthor #6
Tetraspanin CD81 is an adverse prognostic marker in acute myeloid leukemia
201627 citationsauthor #7
Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine
201615 citationsauthor #19
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study.
2016356 citationsauthor #12
Melanoma dormancy in a mouse model is linked to GILZ/FOXO3A-dependent quiescence of disseminated stem-like cells
201631 citationsauthor #13
GILZ overexpression attenuates endoplasmic reticulum stress-mediated cell death via the activation of mitochondrial oxidative phosphorylation.
201619 citationsauthor #4
Mitochondrial oxidative phosphorylation controls cancer cell's life and death decisions upon exposure to MAPK inhibitors
201671 citationsauthor #10
Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents
2016195 citationsauthor #13
Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies
201687 citationsauthor #11
BACH2 promotes indolent clinical presentation in Waldenström macroglobulinemia
20164 citationsauthor #17
Expanded Access Program of GRASPA for treatment of patients with acute lymphoblastic leukemia unable to receive other form of L-Asparaginase: A status update (NCT02197650).
20161 citationsauthor #3
De Novo and Secondary Acute Myeloid Leukemia, Real World Data on Outcomes from the French Nord-Pas-De-Calais Picardie Acute Myeloid Leukemia Observatory
20165 citationsauthor #9
B7‐H3 protein expression in acute myeloid leukemia
201539 citationsauthor #6
Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia
2015106 citationsauthor #16
Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
201546 citationsauthor #9
Correlation Between Bone Marrow Dysplasia and Genomic Profile in De Novo Acute Myeloid Leukemia (AML): A Study By the ALFA Group
20150 citationsauthor #11
Expanded Access Program of Graspa for Treatment of Patients with Acute Lymphoblastic Leukemia Unable to Receive Other Form of L-Asparaginase - a Status Update (NCT02197650)
20151 citationsauthor #3
Quantification of EVI1 transcript levels in acute myeloid leukemia by RT-qPCR analysis: A study by the ALFA Group.
201510 citationsauthor #6
IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association
2015111 citationsauthor #16
Abstract 3216: Immunogenicity and genomic profiling reveal sub-clonal diversity of a murine acute myeloid leukemia (AML) cell line
20150 citationsauthor #3
Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia.
2015237 citationsauthor #15
Monocyte chemoattractant protein 1 (MCP‐1/CCL2) contributes to thymus atrophy in acute myeloid leukemia
201522 citationsauthor #2
French consensus on myelodysplastic syndromes (MDS), and chronic myelomonocytic leukemia: diagnosis, classification and treatment
20150 citationsauthor #20
CD38 in Hairy Cell Leukemia Is a Marker of Poor Prognosis and a New Target for Therapy.
201546 citationsauthor #7
Inversely to DNMT3A, IDH1/IDH2 Are Good Targets for Monitoring Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML): A Pilot Study of the ALFA Group
20141 citationsauthor #15
Azacitidine in untreated acute myeloid leukemia: A report on 149 patients
2014100 citationsauthor #6
5LBA Results of a first-in-man phase I trial assessing OTX015, an orally available BET-bromodomain (BRD) inhibitor, in advanced hematologic malignancies
201414 citationsauthor #2

TIMELINE

1991 0 citations

1993 249 citations

1994 930 citations

1995 168 citations

1996 54 citations

1997 40 citations

1998 353 citations

1999 123 citations

2000 142 citations

2001 79 citations

2002 322 citations

2003 95 citations

2004 265 citations

2005 300 citations

2006 655 citations

2007 1,062 citations

2008 191 citations

2009 866 citations

2010 1,120 citations

2011 2,048 citations

2012 453 citations

2013 439 citations

2014 430 citations

2015 618 citations

2016 811 citations

2017 523 citations

2018 201 citations

2019 346 citations

2020 679 citations

2021 556 citations

2022 81 citations

2023 0 citations

B. Quesnel

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT